Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2025.02.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Jaehwan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of California, Davis, Sacramento, Calif; Dermatology Section, Veterans Affairs Northern California Health Care …. Hauptthemen laut MEDLINE: Psoriasis, Th17 Cells, Antibodies, Monoclonal, T-Lymphocyte Subsets. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, NIAMS.
Abstract (Originalsprache)
BACKGROUND: Recent single-cell studies indicated that IL-17-producing T cells (T17) have diverse subsets expressing IL-17A, IL-17F, or a combination in human psoriasis skin. However, it is unknown how T17 subsets are differently regulated by IL-23 versus IL-17A blockade. OBJECTIVE: We sought to investigate how systemic monoclonal antibody injections blocking IL-23 versus IL-17A differently modify immune cell transcriptomes in human psoriasis skin. METHODS: We analyzed a total of 93 human skin single-cell libraries, including 42 psoriasis pretreatment lesional skin, 25 psoriasis pretreatment nonlesional skin, 12 psoriasis posttreatment after IL-23 inhibition, 4 psoriasis posttreatment after IL-17A inhibition, and 10 control skin samples. CLINICALTRIALS: gov NCT04630652. RESULTS: Of the six T17 subsets identified, an IL17A+IFNG+ subset and an IL17F+IL10- subset expressed the IL-23 receptor along with other inflammatory cytokines, and IL-23 inhibition downregulated these potentially pathogenic T17 subsets. In contrast, T17 cells expressing both IL-17A and IL-17F did not express the IL-23 receptor, and the percentage of this potentially nonpathogenic T17 subset increased after IL-23 inhibition. In addition, the expression of the IL-17-negative regulation genes, such as TNFAIP3, increased in myeloid cells more after IL-23 inhibition than after IL-17A inhibition. CONCLUSIONS: This study suggests multiple immune mechanisms of how IL-23 inhibition can modify the complex inflammatory environment present in psoriatic skin, highlighting the roles of specific T17 subsets in psoriasis development and background skin protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of California, Davis, Sacramento, Calif; Dermatology Section, Veterans Affairs Northern California Health Care System, Mather, Calif; Laboratory for Investigative Dermatology, The R…
- Department of Dermatology, University of California, Davis, Sacramento, Calif; Dermatology Section, Veterans Affairs Northern California Health Care System, Mather, Calif.
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.
- Laboratory of Single-cell Genomics and Population Dynamics, The Rockefeller University, New York, NY.
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY. Electronic address: kruegej@mail.rockefeller.edu.
Förderung
- NIAMS NIH HHS
- NCATS NIH HHS
- NIAMS
- NCATS
Zitieren
APA
Kim, J., Lee, J., Lee, J., Kim, K., Li, X., Zhou, W., Cao, J., & Krueger, J. G. (2025). Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.02.008
Vancouver
Kim J, Lee J, Lee J, Kim K, Li X, Zhou W, et al. Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.02.008
BibTeX
@article{Kim2025,
author = {Kim, Jaehwan and Lee, Jongmi and Lee, Jongeun and Kim, Katherine and Li, Xuan and Zhou, Wei and Cao, Junyue and Krueger, James G},
title = {Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2025.02.008}
}
EUVIMED